Humira: latest news - GoINPHARMA
Wednesday, 23 January 2019 - 23:19

Humira

Why AbbVie is probably the 2019 biotech superstar

AbbVie, headquartered in Illinois, is considered the sleeping giant of the biotech sector by many analysts. AbbVie was established in 2013 as a spin off of Abbott Laboratories and was soon listed (Wall Street). After its IPO its shares increased…

The dynamics of biosimilars market

According to weekly The Economist, biosimilars could become a key to address high healthcare prices in the US, where less than 2% of the population can afford the most advanced and effective therapies, yet such treatments account for 35% of…

How AbbVie protects Humira from biosimilars

Sandoz-Novartis some days ago announced it had reached an agreement with US-based AbbVie. As a result, the launch of Hyrimoz (adalimumab), the biosimilar to blockbuster Humira (adalimumab) was postponed to September 2023. Additionally, the agreement will allow Sandoz to start…

Biosimilar to Humira developed by Boehringer Ingelheim approved in Europe

The European Medicines Agency (EMA) has approved Boehringer Ingelheim’s Cyltezo, biosimilar to AbbVie’s blockbuster Humira. The Agency has recently approved the biosimilar to Humira developed by Amgen as well, which will be marketed as of October 2018 as Amgevita. The…

The evolution of blockbuster business according to JP Morgan

The research for new blockbusters has always been a priority for large pharma groups – a trend expected to continue. According to JP Morgan, an increasing number of drugs from the new category referred to as “personalized and precision medicine”…

Boehringer Ingelheim obtains FDA approval for biosimilar to Humira

Boehringer Ingelheim has obtained approval by the FDA for Cyltezo, the biosimilar to AbbVie’s immunosuppressant Humira. Cyltezo is the first biosimilar by the Germany-based group to be approved and is fairly significant as it provides an alternative to the best-selling…

Biogen’s Imraldi, biosimilar to Humira, approved in Europe

Biogen has announced that the European Commission has approved Imraldi, a biosimilar to Humira. The drug has been co-developed by a Biogen-Samsung Bioepis joint venture. It has been approved for the treatment of rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis…

AbbVie loses fight against Coherus for patent of Humira

The US Patent and Trademark Office ruled in favor of Coherus Bioscience, in dispute with AbbVie over the patent covering Humira. The news caused AbbVie shares to drop by 4%, since Humira alone accounts for more than 60% of the…

Biosimilar to Humira draws closer to commercialization

Boehringer Ingelheim announced today that adalimumab (BI 695501), biosimilar to AbbVie’s Humira, has been accepted to undergo the approval process by both EMA and FDA. Adalimumab is a monoclonal antibody that blocks mediators of inflammation TNF-α. The product is approved…

FDA approves Amjevita, a biosimilar to Humira

FDA has approved Amjevita, as a biosimilar to Humira (adalimumab) for treating multiple inflammatory diseases in adult patients. The drug is indicated for moderately to severely active rheumatoid arthritis, Crohn’s disease, ;active ulcerative colitis and plaque psoriasis. Amjevita has also…